A PROSPECTIVE STUDY TO ASSESS THE QUALITY OF LIFE AMONG THE PATIENTS OF GENERALIZED TONIC-CLONIC SEIZURE RECEIVING TREATMENT PHENYTOIN PLUS CLOBAZAM VERSUS SODIUM VALPROATE PLUS CLOBAZAM THERAPY

Authors

  • Ranjana Sharma Department of Pharmacology, Atal Bihari Vajpayee Government Medical College, Vidisha, Madhya Pradesh, India. https://orcid.org/0009-0001-0268-4202
  • Saroj Kothari Department of Pharmacology, G.R. Medical College, Gwalior, Madhya Pradesh, India. https://orcid.org/0000-0003-3897-273X
  • Akshat Pathak Department of Community Medicine, G.R. Medical College, Gwalior, Madhya Pradesh, India.
  • Prashant Dixit Department of Community Medicine, G.R. Medical College, Gwalior, Madhya Pradesh, India.

DOI:

https://doi.org/10.22159/ajpcr.2024.v17i3.49286

Keywords:

Anti-epileptic drugs, Epilepsy, GTCS, Seizure

Abstract

Objectives: The objective of the study was to compare effect of phenytoin plus clobazam (Group 1) and sodium valproate plus clobazam therapy (Group 2) on quality of life among generalized tonic-clonic seizures (GTCS) patients attending neurology out-patient department at the tertiary care center in Gwalior district.

Methods: The present study was a prospective study conducted between period of February 2019 and January 2020 on 45–45 patients each receiving either phenytoin plus clobazam or sodium valproate plus clobazam dual therapy for the treatment of patients with GTCS. Frequency, percentage, mean, standard deviation, independent student t-test, Chi-square test, and one-way repeated measures of ANOVA were applied, and Bonferroni adjustment was calculated using SPSS version 20 software. P<0.05 was considered to be statistically significant.

Results: For question 1, in Group 1, mean score was 3.29±0.45 at 0 month (baseline), which reduced to 2.51±0.50 and 2.11±0.48 at 3 and 6 months, respectively. In Group 2, mean score was 3.31±0.46 at 0 month, which reduced to 2.35±0.48 and 1.95±0.29 at 3 and 6 months. For question 2, in Group 1, mean score was 3.44±0.54 at 0 month (baseline), which reduced to 2.55±0.54 and 2.22±0.51 at 3 and 6 months, respectively. In Group 2, mean score was 3.64±0.48 at 0 month, which reduced to 2.77±0.55 and 2.44±0.54 at 3 and 6 months, respectively. There was statistically significant improvement seen within the group at 3 and 6 months as compared to baseline in both groups for question 1, question 2, question 3, question 4; p<0.01.

Conclusion: It can be concluded that both combinations of our study groups have a better impact on quality of life from baseline till the end of the study. However, on comparison between them, we have not found a statistically significant difference.

Downloads

Download data is not yet available.

References

World Health Organization. Epilepsy. Available from: https://www. who.int/news-room/fact-sheets/detail/epilepsy [Last accessed on 2022 Jul 22].

Malik NI, Fatima R, Ullah I, Atta M, Awan A, Nashwan AJ et al. Perceived stigma, discrimination and psychological problems among patients with epilepsy. Front Psychiatry 2022;13:1000870. doi: 10.3389/fpsyt.2022.1000870, PMID 36440406

Brodie MJ. Medical therapy of epilepsy: When to initiate treatment and when to combine? J Neurol 2005;252:125-30. doi: 10.1007/s00415- 005-0735-x, PMID 15729515

Dipiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey LM. Pharmacotherapy: A Pathophysiologic Approach. Vol. 4. Connecticut: Appleton and Lange; 2014. p. 141-2.

Sharma HL, Sharma KK. Principles of Pharmacology. 3rd ed. Hyderabad: Paras Publication; 2017. p. 523.

Beghi E. The epidemiology of epilepsy. Neuroepidemiology 2020;54:185-91. doi: 10.1159/000503831, PMID 31852003

Masur H. Scale and Scores in Neurology. New York: Thieme; 2004. p. 323.

Avvaru K, Seepana M, Kotamarthy H. Clinico-demographic profile and treatment seeking behavior of epilepsy patients in tertiary care hospital. Int J Biol Med Res 2012;3:2523-6.

Khan N, Jehan B, Khan A, Khan H. Audit of 100 cases of epilepsy Tertiary Care Hospital. Gomal J Med Sci 2011;9:42-5.

Ahangar JA, Farhat S, Wani RT. Assessment of quality of life in patients on antiepileptic drugs: A hospital based cross sectional study. Int J Basic Clin Pharmacol 2019;8:1532. doi: 10.18203/2319-2003.ijbcp20192634

Kotsopoulos IA, van Merode T, Kessels FG, de Krom MC, Knottnerus JA. Systemic review and meta-analysis of incidence studies of epilepsy and unprovoked seizures. Epilepsia 2002;43:1402-9. doi: 10.1046/j.1528-1157.2002.t01-1-26901.x, PMID 12423392

Pal SK, Sharma K, Prabhakar S, Pathak A. Neuroepidemiology of epilepsy in Northwest India. Ann Neurosci 2010;17:160-6. doi: 10.5214/ ans.0972.7531.1017404, PMID 25205899

Santhosh NS, Sinha S, Satishchandra P. Epilepsy: Indian perspective. Ann Indian Acad Neurol 2014;17:S3-11. doi: 10.4103/0972- 2327.128643, PMID 24791085

Weinstock A, Agarwal N, Farooq O, Cheema Z, Hamilton D, Parrish J. Evaluation of the effects of clobazam on seizure control and quality of life in children with Lennox-Gastaut syndrome: A pilot study. J Child Neurol 2019;34:432-9. doi: 10.1177/0883073819836534, PMID 30913948

Published

07-03-2024

How to Cite

Sharma, R., S. Kothari, A. Pathak, and P. Dixit. “A PROSPECTIVE STUDY TO ASSESS THE QUALITY OF LIFE AMONG THE PATIENTS OF GENERALIZED TONIC-CLONIC SEIZURE RECEIVING TREATMENT PHENYTOIN PLUS CLOBAZAM VERSUS SODIUM VALPROATE PLUS CLOBAZAM THERAPY”. Asian Journal of Pharmaceutical and Clinical Research, vol. 17, no. 3, Mar. 2024, pp. 96-99, doi:10.22159/ajpcr.2024.v17i3.49286.

Issue

Section

Original Article(s)